Euro
USD
British Pound
NULL
Product Description
LRG1 binds cytochrome c, an initiator/amplifier of programmed cell death (apoptosis), and by binding cytochrome c, is thought to play a role in cell survival. LRG1 is a biomarker associated with several cancers, including non-small cell lung cancer, colorectal cancer, and pancreatic cancer. Recent studies have shown it is three-fold more abundant in ovarian cancer serum compared to non-cancer control serum. LRG1 levels are only moderately correlated with CA125 levels. Elevated levels of LRG1 in the cerebral spinal fluid are being studied as markers for the early diagnosis of Parkinson's disease and progressive supranuclear palsy. In normal plasma, LRG1 has a concentration of 21-50 ug/ml. It is an acute phase protein with levels elevated in patients with bacterial infections; interestingly, during the inflammatory response, LRG1 levels are not correlated with CRP levels.
Biovision | P1431 | Leucine-rich Alpha 2 Glycoprotein-1 (LRG1), Human Plasma DataSheet
Biomolecule/Target :
Synonyms: Leucine-rich alpha-2-glycoprotein, LRG, LRG1
Alternates names: Leucine-rich alpha-2-glycoprotein, LRG, LRG1
Taglines: An initiator/amplifier of programmed cell death (apoptosis)
NCBI Gene ID #: 116844
NCBI Gene Symbol: LRG1
Gene Source: Human
Accession #: P02750
Recombinant: False
Source: Human Plasma
Purity by SDS-PAGE: >95%
Assay: SDS-PAGE.
Purity:
Assay #2:
Endotoxin Level:
Activity (Specifications/test method):
Biological activity:
Results:
Binding Capacity:
Unit Definition:
Molecular Weight: 50,000
Concentration:
Appearance: Sterile Filtered colorless solution
Physical form description: Liquid
Reconstitution Instructions:
Amino acid sequence:
Handling: Centrifuge the vial prior to opening.
Usage:
